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Nowadays we understand cell membranes not as a simple double lipid layer but as a collection of com-
plex and dynamic protein–lipid structures and microdomains that serve as functional platforms for inter-
acting signaling lipids and proteins. Membrane lipids and lipid structures participate directly as
messengers or regulators of signal transduction. In addition, protein–lipid interactions participate in
the localization of signaling protein partners to speciﬁc membrane microdomains. Thus, lipid alterations
change cell signaling that are associated with a variety of diseases including cancer, obesity, neurodegen-
erative disorders, cardiovascular pathologies, etc. This article reviews the newly emerging ﬁeld of mem-
brane lipid therapy which involves the pharmacological regulation of membrane lipid composition and
structure for the treatment of diseases. Membrane lipid therapy proposes the use of new molecules
speciﬁcally designed to modify membrane lipid structures and microdomains as pharmaceutical
disease-modifying agents by reversing the malfunction or altering the expression of disease-speciﬁc
protein or lipid signal cascades. Here, we provide an in-depth analysis of this emerging ﬁeld, especially
its molecular bases and its relevance to the development of innovative therapeutic approaches.
 2015 Published by Elsevier Ltd.45, neutral
myeloid
glycerol;
atty acid
glioside;
; Hsp70,
omains;
; NMDA,
domain,
linositol
pase A2;
domain,
tor; S1P,
linases);
gulatory
very low
lecular
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
2 P.V. Escribá et al. / Progress in Lipid Research xxx (2015) xxx–xxx
JPLR 878 No. of Pages 15, Model 5G
12 May 2015ContentsP
b1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2. Molecular bases underlying MLT. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00lease
ase f2.1. Membrane microdomains:signaling platforms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2.2. G proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2.3. Protein kinase C. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2.4. Sphingomyelin synthase and cell proliferation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2.5. The stress response . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
2.6. Heterogeneity of membrane composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 003. Molecular bases of targeting the plasma membrane . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3.1. Type 1: direct regulation through membrane structure modification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3.2. Type 2: regulation of enzymatic activity to alter membrane lipid levels . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3.3. Type 3: modulation of gene expression that results in changes in membrane lipid structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3.4. Type 4: lipid alterations that affect protein–protein interactions in specific membrane microdomains. . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
3.5. Type 5: direct MLT-drug binding to a protein that alters its membrane binding affinity or that of other signaling proteins . . . . . . . . . . . 004. Therapeutic areas where MLT has been developed . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.1. Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.2. Metabolic diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 004.2.1. Obesity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.2.2. Diabetes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.2.3. Hypercholesterolemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.2.4. Metabolic syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 004.3. Cardiovascular diseases: hypertension. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.4. Neurodegenerative disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 004.4.1. Alzheimer’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
4.4.2. Spinal cord injury and other neurological conditions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 004.5. Other pathologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
5. Future directions and conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 00111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
1401. Introduction
Since the ﬁrst general structure of cellular membranes was pub-
lished in the 1970s by Singer and Nicolson [1] numerous studies
have expanded upon this to further deﬁne its complex structure.
In a cell membrane bilayer, hundreds to thousands of different
lipid species form a heterogeneous cell boundary with multiple
structural and functional properties [2]. The same membrane
sequestration strategy that separates the interior of cells from
the rest of world is also used for separating the cellular interior
into a collection of membrane-bound organelles. The lipid classes
that form the different types of cell membranes (Fig. 1) are usually
not homogeneously distributed but can form microdomains that
act as complex signaling platforms (together with proteins) due
to their membrane lipid (structure) preferences. For example,
interaction of receptor tyrosine kinases (e.g., EGFR) with Ras, and
of Ras with Raf, to propagate proliferation signals into the cell
beneﬁts from their common preference for certain membrane
microdomains to establish physical productive interactions [3].
Similarly, G protein-coupled receptors (GPCRs) and G proteins
exhibit similar membrane lipid environment preferences [2,4,5].
Membrane functions are altered in a wide range of human dis-
eases and this has led to the concept that components of the
plasma membrane, for example, speciﬁc lipids, enzymes or tran-
scription factors can be targeted to alter its composition and struc-
ture [6–8]. This, in turn, would affect the localization and activity
of key proteins, or key protein–protein interactions in speciﬁc
membrane microdomains, and thereby affect signaling cascades.
This approach is termed membrane lipid therapy (MLT). Indeed,
several studies have now demonstrated the potential of MLT and,
although the ﬁrst clinical trials of rationally designed lipids to reg-
ulate the membrane composition and structure to treat cancer and
diabetes only began recently (e.g., ClinicalTrials.gov Identiﬁercite this article in press as: Escribá PV et al. Membrane lipid therapy: M
or drug discovery and new disease treatment. Prog Lipid Res (2015), httNCT01792310), other trials using natural lipids were already ongo-
ing (e.g., docosahexaenoic acid (DHA) for Alzheimer’s disease:
ClinicalTrials.gov Identiﬁer NCT00440050). In this article, the ratio-
nale behind targeting the plasma membrane and the different
approaches that can be used to modulate its lipid composition,
structure and function is provided. Later, we discuss the current
state of the art in various therapeutic indications.2. Molecular bases underlying MLT
A great many cellular functions occur in or around membranes
[2], which suggests that changes in the membrane composition
and structure could be relevant in the proper functioning of the
cells. In the plasma membrane, hundreds of different lipid species
can be found. Some of them have a negative charge, which can
promote interactions with positively charged amino acids in
proteins [4,7]. Other lipids have a small polar head (e.g., phos-
phatidylethanolamine), allowing docking of bulky protein lipid
anchors (e.g., isoprenyl moieties present in Ras: [9]). Other mem-
brane lipids have a bigger polar head and form tightly packed areas
where only certain fatty acids (e.g., myristic or palmitic acid) can
intercalate to aid proteins (e.g., Ga protein) bind to membrane
regions where these lipids are abundant. Therefore, the membrane
lipid composition can have a profound role in cell signaling.
Changes in the type and abundance of lipids in membranes induce
alterations in the propagation of cell messages that can be associ-
ated with pathological states or with its therapy. In the following
paragraphs we will describe important structural features of mem-
branes and proteins that participate in protein–lipid interactions
and can be regulated by MLT drugs.
Thus, it has been seen that a high consumption of saturated or
trans-unsaturated fatty acids induce increases in the proportion ofodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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Fig. 1. Lipid composition of biological membranes. (A) Lipid composition of subcellular compartments expressed as mol% of the total cell lipid content. Insert: average lipid
composition of a mammalian cell. (B) Distribution of lipids among subcellular compartments expressed as mol% of the total amount of a given lipid class in the whole cell.
Data were renormalised by combining previously published data on subcellular lipid compositions [204–206] with surface area of the corresponding subcompartment [207].
Graphical data were converted to numerical values and adjusted to the same average sum. These were then multiplied by the relative surface areas of the corresponding
subcompartments (IA). For (B) each lipid class was set to 100%. ER, endoplasmic reticulum; Mit, mitochondria; PM, plasma membrane; ES + LS, Endosomes and Lysosomes;
PC, phosphatidylcholine; PE, phosphatidylethanolamine; SM, sphingomyelin; PI, phosphatidylinositol; BMP, bis(monoacylglycero)phosphate; cl, cardiolipin
(diphosphatidylglycerol).
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12 May 2015saturated and decrease of unsaturated fatty acids in cell mem-
branes [10]. Membrane fatty acid composition changes may, in
turn, alter receptor mediated cell signaling (e.g., [11]) and cause,
among other health problems, cardiovascular diseases [12].
Different fatty acids can have speciﬁc effects on the membrane
lipid structure and the formation of membrane microdomains
[13,14]. Their inﬂuence on the membrane lipid structure can then
alter the propagation of signals from G protein-coupled receptors
to G proteins, exerting an even greater control on cell signals than
receptor agonists and antagonists [8]. Therefore, it is feasible to
design therapeutic interventions targeting the membrane lipid
composition and structure [5].184
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2022.1. Membrane microdomains:signaling platforms
Lipids are not usually homogeneously distributed in the mem-
brane. They form microdomains that confer speciﬁc
physico-chemical properties to discrete regions of the bilayer. A
variety of raft microdomains with different compositions and bio-
physical properties have been reported [15]. Sphingomyelin (SM),
glycosphingolipids (GSLs) and cholesterol (Chol) are abundant in
lipid rafts, and form rigid and liquid ordered (Lo) microdomains.
Regions with higher phosphatidylethanolamine (PE) content are
more ﬂuid and have a weaker surface pressure because the small
polar heads of these lipids produce a lower surface packing density
and greater lipid disorder (liquid disordered microdomains, Ld)
[16]. The heterogeneous distribution of lipids gives rise to both
transient (e.g., lipid rafts, caveolae, coated pits, etc.) or stable
(e.g., synaptosomes, tight junctions, brush border, etc.) membrane
microdomains, a segregation that is favoured by lipids such as Chol
[17,18] and speciﬁc proteins [15,17].
Proteins involved in signal transduction interact with distinct
membrane microdomains, and the association converts thesePlease cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httstructures into signaling platforms (termed signalosomes) essen-
tial for the cell’s physiology. Moreover, they may contain incom-
plete signaling cascades that can be activated when one further
signaling entity (e.g., the receptor) is recruited to the lipid raft
[19]. Both physiological and pathological situations can change
the cell membrane lipid composition, the biophysical properties
of microdomains, and consequently, the proteins they contain
and the signals they propagate. In fact, alterations in lipid raft com-
position and structure have been associated with different
pathologies [20,21] and therefore, drug-induced regulation of
membrane lipid composition and structure (MLT) can modulate
cell signaling, offering potentially effective treatments for a variety
of conditions [5,22–24].2.2. G proteins
G proteins constitute an example of extrinsic membrane pro-
teins whose localization to membrane microdomains and activa-
tion is regulated by their interaction with membrane lipids. In
the vicinity of GPCRs, there is generally a molar excess of the het-
erotrimeric (pre-active protein made up of one alpha, beta and
gamma subunit, Gabc) G proteins to ensure signal ampliﬁcation.
The Gabc binding to the Ld regions of the membrane is promoted
by (i), the bulky isoprenyl moiety of the Gc subunit, and (ii) the
combined action of PE and the membrane spanning helices of
GPCRs to induce a non-lamellar phase propensity [4,9,25]. Upon
ligand binding, GPCR-mediated activation of the G protein causes
the exchange of GDP for GTP in the Ga subunit, which dissociates
from the Gbc dimer and translocates to lipid rafts due to its greater
preference for Lo microdomains [4]. In Lo microdomains, the Ga
subunit may activate effector proteins, like adenylyl cyclase, phos-
pholipase C or ion channels among many. By contrast, the Gbc
dimer remains in the Ld microdomains, due to the isoprenylodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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of Gc, and it either recruits G protein-coupled receptor kinase
(GRK) to phosphorylate and inactivate the GPCR, or it activates
other effectors [26,27]. Phosphorylated GPCR molecules can be
bound by b-arrestin and translocated from the Ld microdomains
to clathrin microdomains (coated pits), where the receptor will
be internalised by endocytosis. Subsequently, its activity can be
restored by phosphatases and its recycling to the plasma mem-
brane [26]. In this context, controlling membrane composition
and structure can be used to treat pathologies where GPCRs and/or
G proteins are altered.
2.3. Protein kinase C
Upon activation, protein kinase C (PKC) isozymes are translo-
cated to the plasma membrane, where they become activated
and phosphorylate a wide variety of protein targets. Recruitment
of PKC to Ld membrane microdomains is favoured by: (i) its speci-
ﬁc interactions with the HII-prone lipid DAG, and the negatively
charged lipids phosphatidylserine (PS) and phosphatidylinositol
(PI); and/or (ii), its preference for microdomains with high
non-lamellar phase propensity (rich in PE, DAG, etc.) [28].
Moreover, reducing the non-lamellar (HII) phase propensity by
the anticancer drug daunorubicin induces PKCa translocation to
the cytoplasm, whereas an increase in the non-lamellar phase
propensity (produced by adding PE) provokes the recovery of
PKCa at the membrane [29].
PKC binding to membranes is not only regulated by lipid struc-
tures but also by speciﬁc membrane lipids, both factors that deﬁne
its sub-localization to speciﬁc membrane microdomains [28]. Thus,
the C1 domain in the N-terminal region of conventional and novel
PKC isozymes can bind to the HII-prone lipids, DAG and phorbol
esters, and it possibly recognizes non-lamellar phases [30]. By con-
trast, the C1 domain of atypical PKC isozymes recognizes ceramide
(Cer) [30]. The C1 domain of PKCa and b contains a Cys and His rich
motif that tightly binds two zinc ions and one DAG or phorbol ester
molecule. In addition, Asp residues in the C2 domain (which lies
near the C1 domain in the regulatory region of the enzyme) of con-
ventional and novel PKC isozymes participate in the binding of Ca2+
ions, which is necessary for the further binding of PS and its
cytosol-to-membrane translocation [31,32]. Moreover, basic amino
acid residues (e.g., Asn and Arg) participate in the binding of addi-
tional acidic phospholipid molecules. The presence (conventional
and novel) or absence (atypical) of C2 domains, or the molecular
differences found in this motif, explain the different protein–lipid
interactions among PKC isozymes and the ﬁne-tuning that under-
lies their differential membrane localization [33]. For example, a
Lys rich cluster in the C2 domain also binds the membrane phos-
pholipid, phosphatidylinositol 4,5-bisphosphate (PIP2), inducing
PKCa activation in a manner distinct from that of other membrane
lipids [34]. Some studies indicate that the presence of PIP2 deter-
mines the localization of the enzyme to the plasma membrane
but not to other internal membranes [35]. Therefore, interactions
of PKC isozymes with deﬁned lipids or lipid structures in part
determine the type of targets that the enzyme will phosphorylate
in a given microdomain of the cell’s membranes [30].
The C2 domain that is present in PKC and other proteins is
not the only lipid-interacting domain that recognizes
phosphoinositides. Diverse protein motifs (e.g., pleckstrin homol-
ogy [PH] domains, FYVE zinc ﬁnger domains, PX domains,
epsin N-terminal homology [ENTH domains, clathrin assembly
lymphoid myeloid [CALM] domains, PSD95-Dlg1-zo-1 [PDZ]
domains, phosphotyrosine-binding [PTB] domains, 4.1
protein-ezrin-radixin-moesin [FERM] domains, etc.) can bind differ-
ent inositol lipids that localize to different cell membranes [36]. The
presence of phosphoinositides in speciﬁc membranemicrodomainsPlease cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httfacilitates protein docking to these membrane regions and, more-
over, some of these protein domains themselves are also directly
involved in protein–protein interactions (e.g., PH and PTB domains)
[37]. In some cases, these protein domains mediate the binding to
various phosphoinositides. Thus, differences in the PH domain
sequence produce variations in protein afﬁnity and in the speciﬁcity
for the various forms ofmembrane phosphoinositides (such as PIP2,
PIP3, etc.) [38]. In other cases, the PI recognition domain has a more
deﬁned preference in different proteins, such as the FYVE domain
that appears in proteins that regulate vesicular sorting through
speciﬁc interactions with PI3P [39].
In summary, deﬁned membrane lipid classes, such as acidic
phospholipids (e.g., PS or PI), PE or DAG, and membrane lipid
structures, such as HII-prone or lamellar-prone (Lo or Ld) bilayers,
inﬂuence the localization of proteins to membrane microdomains
via protein–lipid interactions, facilitating speciﬁc protein–protein
interactions and their resulting signals [28,29,31,32,34].
Therefore, regulating the membrane lipid composition through
pharmaceutical or nutraceutical interventions can serve to normal-
ize signals that have been altered under different (pathological)
conditions.
2.4. Sphingomyelin synthase and cell proliferation
Membrane lipid composition can be altered by food intake but
is mainly controlled by regulation of the activity of a number of
enzymes. While many enzymes are important in the cell’s physiol-
ogy, the relevant role of sphingomyelin synthase (SGMS) has been
highlighted recently. This enzyme catalyzes the reversible conver-
sion of PC and Cer into SM and DAG. Recent studies showed that
tumor cells, with uncontrolled proliferation have lower levels of
SM and higher of PE than non-tumor cells [40]. The ca. 10-fold dif-
ference in the PE:SM ratio between proliferating cancer cells and
normal cells has been suggested to constitute a switch that would
enable certain type of proliferation signaling proteins to bind to the
membrane and propagate cell growth messages when the cell has
a high PE:SM ratio [41].
2.5. The stress response
Cells and their membranes respond rapidly to various environ-
mental perturbations. It has been demonstrated that subtle mem-
brane alterations are critically involved in the conversion of signals
from the environment into the transcriptional activation of stress
genes (e.g. heat shock protein (Hsp) genes) [42]. Moreover, the
speciﬁcity of the stress gene expression can be regulated by the
particular occurrence and distribution of membrane microdomains
(rafts, caveolae, lipid shells, etc.) that precisely sense biological and
physical changes [43,44].
Furthermore, it has also been shown that interactions between
speciﬁc domains of membranes and certain Hsps remodel the
pre-existing architecture and physical order of membranes [45].
This feed-back loop allows interactions which antagonize the
heat-induced membrane lipid disorganization and can preserve,
at least temporarily, membrane structure and functions during
stress. Since highly speciﬁc Hsp–lipid interactions are known,
these provide a means of targeting Hsps to distinct compartments
in the membrane such as lipid rafts which are known to be central
to many signaling pathways [6].
Linking membrane microdomain structure and physical states
with the regulation of heat shock gene expression, together with
the feedback effect of certain Hsps in restoring membrane struc-
ture/function, may represent a ‘unifying theory’ in which mem-
brane microdomains are key players in a new modality of gene
expression [42]. This implies a new way of controlling membrane
signaling cascades through physical state which consequentlyodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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Fig. 2. Mechanisms of action of molecules acting via MLT. The colored squares
represent different membrane microdomains with deﬁned compositions and
structures. The brown arrows indicate the sites of action (lipid or protein).
Numbers 1 through 5 correspond to type-1 to -2 membrane modulation molecular
mechanisms of action (MMoA). Type 1 involves direct binding of the compound to
the membrane, which alters the interaction of one or more proteins with the
membrane (number 1 in this ﬁgure). MMoA type 2 involves modiﬁcation of the
activity of an enzyme that changes the composition of the membrane (number 2).
MMoA type 3 involves regulation of gene expression that causes changes in the
activity of an enzyme that regulates the membrane composition (a), changes in
protein–lipid interactions (b) or in protein–protein interactions at the membrane
(number 3). Changes in the composition of membrane microdomains or molecules
that using other means alter protein–protein interactions at the membrane would
be considered type-4 membrane lipid therapy approaches. Finally, protein alter-
ations that affect their interaction with the membrane constitute type-5 membrane
lipid therapy approaches (number 5).
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Section 3.1).
2.6. Heterogeneity of membrane composition
The lipid and protein composition of plasma membranes from
different cell types is very different. Therefore, the presence or
absence of given lipids will differentially affect the biophysical
properties of the lipid bilayer and protein activities. Moreover,
the individual membrane microdomains in the same cell mem-
brane will be differentially affected by the presence or absence of
a given molecule (see below the effect of Cer on Chol-rich lipid
rafts). Thus, monounsaturated fatty acid treatments can change
the order of Lo and Ld microdomains [40,46]. In addition, the cell
is full of organelles and membranous structures with speciﬁc lipid
and protein compositions. In this scenario, all players can be
modulated by MLT approaches. Thus, the overall membrane lipid
composition, the composition of membrane microdomains or the
composition of internal organelles can be targeted by natural or
modiﬁed lipids or drugs [47–49]. In this context, fatty acids regu-
late the biophysical properties of membranes according to their
structure. Thus, the cis-monounsaturated fatty acid, oleic acid,
induces the formation of nonlamellar phases in model membranes,
whereas its saturated (stearic) and trans-monounsaturated (elai-
dic) analogues do not [13]. The type and abundance of different
lipid classes and their fatty acid composition deﬁne the types of
membrane microdomains that form platforms where signaling
partners have productive interactions. This has been used to design
synthetic fatty acids that regulate the membrane microdomain
organization in a similar fashion to that of natural lipids [14].
This approach has been used to regulate protein–protein
interactions in lipid rafts and other membrane microdomains
[41,50]. Thus, MLT appears to be an elegant approach to make pro-
tein–protein interactions susceptible to drug therapy where they
are frequently considered to be a difﬁcult target [51].
In general, membranes are formed by hundreds of different
lipid molecular species and they participate in different functions
either as single molecules or as structures formed by several mole-
cules. The multiple functions of membranes depend on these
lipids, which confer relevant functions to cells. For example, it
has been recently reported that the membrane lipid composition
constitutes a proliferation switch in tumor cells [47].400
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4233. Molecular bases of targeting the plasma membrane
We describe ﬁve different types of regulatory effects in which
the plasma membrane is involved (Fig. 2) and can be exploited
for therapeutic purposes. These classiﬁcations are based on the
way the membrane lipid composition is regulated or
protein-membrane interactions are controlled.
3.1. Type 1: direct regulation through membrane structure
modiﬁcation
Lipids acquired in diet, or by nutraceutic and pharmaceutic
interventions can be incorporated into cell membranes, where they
regulate the physico-chemical properties of membranes that, in
turn, control the localization and activity of extrinsic membrane
proteins (Fig. 2, panel 1). Thus, monomeric Ga proteins prefer
lamellar membrane regions with high surface pressure, whereas
dimeric or heterotrimeric G proteins prefer nonlamellar-prone
microdomains with loose membrane surface packing [4,7]. This
fact is due to the presence of a bulky isoprenyl moiety in the Gc
subunit of G protein dimers and trimers that cannot penetrate well
into bilayers with dense packing. By contrast, Ga proteins havePlease cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httfatty acyl moieties that prefer lamellar membrane structures. In
this context, the presence of oleic acid but not its trans analogue
(elaidic acid) in membranes causes changes in the lipid surface
packing that alter G protein-mediated a2-adrenoceptor signaling
with a greater potency than agonist ligands [8]. Moreover, anti-
cancer drugs that regulate the membrane structure also regulate
the interaction of G proteins with the membrane and downstream
signaling [29,52].
Molecular chaperones [53] mediate the assembly of numerous
proteins and degradation of misfolded proteins and are associated
with membranes via speciﬁc lipid interactions [45,54]. The heat
shock response (HSR) can be activated by diverse environmental
and physiological stressors that result in the immediate induction
of stress genes encoding heat shock proteins (Hsp), molecular
chaperones, proteases and other proteins [55]. According to the
denatured protein sensor hypothesis, misfolded or aggregated pro-
teins disturbing cell homeostasis may represent a common sensory
element [56]. However, membranes also sense environmental
changes and, by altering their physical state and microdomain
organization, they alter heat shock signals that activate Hsp tran-
scription [42] (Fig. 3).
The formation of isoﬂuid membrane states in response to the
application of heat shock, the local anesthetic benzyl alcohol
(BA), or other chemical agents results in almost identical increases
in Hsp70 expression in B16F10 cells [57]. Importantly, BA induced
activation of Hsp expression is not triggered by a protein unfolding
signal but rather by membrane hyperﬂuidization, which is fol-
lowed by a rapid structural remodeling of the membrane lipids
[58–63].
The raft components SM and Chol are also involved in the gen-
eration of second messengers in the HSR, and membrane stress
caused by heat or chemical membrane ﬂuidization augments the
total Cer levels in Jurkat cells [64]. A direct link between
heat-induced Cer production and the induction of speciﬁc stress
proteins has been described in NIH WT-3T3 cells [65].
Application of the exogenous Cer analogue C2-Cer, or increasingodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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Fig. 3. Overview of surface membrane-controlled signal transduction pathways that potentially control the expression of Hsps via HSF1. AA, arachidonic acid; Akt, protein
kinase B; CaMKII, calcium/calmodulin-dependent protein kinase II; Cer, ceramide; Chol, cholesterol; DAG, diacylglycerol; DGL, diacylglycerol lipase; GFR, growth factor
receptor; GSK3, glycogen synthase kinase-3; HSF1, heat shock factor 1; IP3, inositol triphosphate; MAPK, mitogen-activated protein kinase; MGL, monoacylglycerol lipase;
PI3K, phosphoinositide 3-kinase; PIP2, phosphatidylinositol-4,5-biphosphate; PIP3, phosphatidylinositol-3,4,5-triphosphate; PKC, protein kinase C; PLA2, phospholipase A2;
PLC, phospholipase C; PTEN, phosphatase and tensin homologue protein; Rac1, Ras-related C3 botulinum toxin substrate 1; S1P, sphingosine-1-phosphate; SM,
sphingomyelin; SMase, sphingomyelinase; SPC, sphingosylphosphorylcholine. The ﬁgure is not intended to show the precise localization of all the components. For further
details see text.
6 P.V. Escribá et al. / Progress in Lipid Research xxx (2015) xxx–xxx
JPLR 878 No. of Pages 15, Model 5G
12 May 2015endogenous intracellular Cer induces the sHsp ab-crystallin, but
not the structurally related Hsp27. Cer has the unique property
of fusing membranes and it appears to drive the coalescence of raft
microdomains to form large, Cer-enriched membrane platforms
that lack Chol [66,67]. Thus, elevated Cer levels rapidly
displace Chol from the membrane/lipid-‘‘Chol-raft’’ to form a
‘‘Cer-raft’’ [68], which might be required for biochemical
transfer of stress signals across the plasma membrane.
Sphingosylphosphorylcholine (SPC), another sphingolipid metabo-
lite activates Hsp27 via the p38 MAPK pathway in isolated rat
cerebral arteries, unlike sphingosine-1-phosphate (S1P) [69]. By
contrast, in osteoblast-like MC3T3-E1 cells and aortic smooth mus-
cle A10 cells, S1P stimulates Hsp27 induction via the p38 MAPK
and PI3K/Akt pathways [70–72]. In addition, during HSR, Chol
can be rapidly converted to cholesteryl glucoside [73]. Indeed,
exogenous cholesteryl glucoside rapidly activates the transcription
factor HSF1 and induces the synthesis of Hsp70 in ﬁbroblasts [74].
These ﬁndings suggest that lipids are important in ﬁne tuning the
expression of Hsp chaperones, which may prove beneﬁcial in the
treatment of several important diseases, such as cancer, diabetes
and various neurodegenerative diseases [44].
A special case of Type 1 MLT is the so-called lipid replacement
therapy. A well-known example of this approach is the substitu-
tion of membrane lipids in mitochondria. This organelle carries
out oxidative phosphorylation to produce energy, so that it is more
prone to produce reactive oxygen species that can damage mito-
chondrial lipids, especially in association with aging [75]. Some
studies have demonstrated that therapeutic interventions with
lipids and antioxidants can reduce mitochondrial lipidPlease cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httperoxidation and replace damaged lipids, which results in a reduc-
tion of fatigue in elderly subjects [76]. Altered mitochondrial mem-
brane lipids affect the activity of important mitochondrial proteins,
and treatments with cardiolipin, rich in the polyunsaturated fatty
acid linoleic acid, restore the membrane lipid structure and activity
of Ca2+ channels in mitochondria [77].
3.2. Type 2: regulation of enzymatic activity to alter membrane lipid
levels
One example of Type 2 MLT is the effect of hydroxy-C18 unsat-
urated FAs (hydroxyoleic, hydroxylinoleic, hydroxy-a-linolenic
and hydroxy-c-linolenic acids) on SGMS [40]. The dramatic
increases in SM levels following human cancer (lung, glioblastoma
multiforme, astrocytoma, leukemia or in cell (A549, U118, SF767,
Jurkat and others) treatment with these synthetic FAs (up to
500% following exposure for 72 h) produces signiﬁcant alterations
in the localization of pivotal proteins involved in cell proliferation,
such as the translocation of Ras from the plasma membrane to the
cytosol [40,41]. Alterations in the activity of enzymes that partici-
pate in the metabolism of sphingolipids (such as S1P or Cer) are
implicated in many diseases, including cancer [78], suggesting that
MLTs may be designed to regulate sphingolipid activity (Fig. 2
panel 2).
Changes in the composition of membranes are also observed in
B16F10 cell cultures following thermal stress or benzyl alcohol
treatment, which activates certain phospholipases (mainly PLA2
and PLC), and causes loss of polyenes (including the potent HSR
modulator arachidonic acid, AA) and concomitant increases inodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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12 May 2015saturated lipid species [58]. Moreover, in CHO cells at elevated,
fever-type heat shock temperatures glycosyl-phosphatidylinositol
labeled clusters (rafts) disappeared, which was accompanied by
an increase in the expression of the small heat shock protein
Hsp27 [60]. It is noted that in cell cultures, raft integrity sponta-
neously recovers at fever-like temperatures [79]. This effect causes
redistribution of Chol-rich plasma membrane domains [61,80] and
increased membrane lipid packing density in cell cultures [39],
with a concomitant change in the localization of relevant signaling
proteins. MLT drugs (Bimoclomol, BGP-15) affecting the composi-
tion and dynamics of rafts can modulate the expression of certain
hsp genes in different cell cultured cells [81–83].
3.3. Type 3: modulation of gene expression that results in changes in
membrane lipid structure
Certain DNA-associated phospholipids are found in the nuclear
matrix, where their regulatory roles are as yet unknown [84]. Many
aspects of lipid metabolism and function in the cytoplasm are reca-
pitulated in the nucleus, and thus, MLT can also target nuclear or
other membranes [84]. The nuclear envelope contains the bulk of
nuclear lipids, while the nuclear matrix contains enzymes and
metabolites necessary for autonomous lipid metabolism in the
nucleus [85]. The presence of nuclear lipids and their regulatory
effects on numerous nuclear functions have been well documented
(e.g., [85]. In this scenario, both the lipid-mediated regulation of
nucleic acid function and the control of lipid composition in the
nuclear membrane constitute potential activities with which MLT
can interact.
Quiescent differentiated cells have high SM levels in the PM,
whereas proliferating cells, including cancer cells, exhibit reduced
PM SM content [40]. Direct addition of SM to the culture medium
does not induce cell cycle arrest, whereas induction of SGMS and
the subsequent increase in SM levels does inhibit cell growth and
differentiation [40,41]. Interestingly, low nuclear SM has been
associated with cell proliferation [86]. Because DNA synthesis is
activated when sphingomyelinase is active and SGMS activity is
reversed, it could be speculated that part of the actions mediated
by MLT could occur in the cell nucleus. In this scenario, MLT may
be able to regulate gene expression, thereby modifying lipid com-
position (Fig. 1). Regulating the expression of genes that alter the
lipid composition of the membrane can alter cell activity in various
ways. The lipid-binding transcription factors PPARs, RXR, RAR and
LXR, can be regulated by synthetic ligands, resulting in the modu-
lation of membrane lipids and cell function [87]. Since lipids con-
trol the activity of PPARs and related transcription factors, the
activity of these proteins could be regulated by hydrophobic MLT
drugs, such as fatty acid analogues, whose partition coefﬁcients
are higher than those recommended by the Lipinski’s rule of 5 to
design or discover drugs. This rule suggests (among other things)
that the partition coefﬁcient (log Poctanol/water) should be less
than 5 and this may fail for certain MLT molecules, such as modi-
ﬁed fatty acids [88].
3.4. Type 4: lipid alterations that affect protein–protein interactions in
speciﬁc membrane microdomains
The modiﬁcation of membrane lipids in this scenario affects the
productive interaction of 2 signaling partners (Fig. 2 panel 4).
Accordingly, the changes in membrane lipid composition and
structure may alter a given microdomain or the afﬁnity of one of
the proteins involved in the transduction of a speciﬁc signal. For
example, reductions in the PE-to-SM ratio diminish the RTK–Ras
and Ras–Raf interactions at the membrane, provoking a concomi-
tant reduction in MAPK-associated signaling and ultimately, in
the proliferation of cancer cells [41].Please cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httIn a similar fashion, membrane Chol profoundly affects the tar-
geting of the small GTP-binding protein Rac1 to membranes and its
interactions with other proteins [89]. The stress-stimulated
PI3K-driven conversion of PIP2 to PIP3 has been proposed to acti-
vate Rac1 under mild, non-denaturing stress conditions [55], and
Rac1 may be involved in mild HS-induced Hsp expression [90].
Accordingly, the redistribution of Chol-rich membrane domains
may alter stress responses through Rac1-dependent mechanisms.
Indeed, Rac1 inhibition by a speciﬁc inhibitor (NSC233766) halves
HS-induced hsp25 expression at fever-like temperatures [79,91].
Clearly, there is a complex network of interconnected pathways
that bridge the gap between the cell membrane and HSF-1 medi-
ated modulation of the expression of Hsp chaperons (see Fig. 2).
Stress-induced inositol phosphate signals are generated within
minutes and they turnover rapidly [92]. Rapid increases in cytoso-
lic Ca2+ levels [57,93] are a prerequisite for hsp transcription [94],
although in human epidermoid A431 cells heat activates the
Na+–Ca2+ exchange system, thereby augmenting [Ca2+]i while
reducing [Na+]i [95]. In addition, the HSR is triggered by
calcium/calmodulin-dependent protein kinase II (CaMKII) which
is activated by increases in [Ca2+]i, the binding of
Ca2+/calmodulin and by autophosphorylation [96]. The HSR can
also be activated by both AA and PLA2 [97,98]. Exogenous PLA2
stimulates AA generation and release, while AA production can
be driven by DAG lipase-MAG lipase metabolism of DAG. A positive
correlation was recently demonstrated between HS response and
cellular AA content [62]. Elevations in [Ca2+]i, PKC phosphorylation
and protein–protein interactions can regulate PLA2 activity [99].
Moreover, the generation of cis-unsaturated FAs by PLA2 is crucial
for the activation of PKC, and may stabilize PKC in an activated
state [100,101]. AA may serve to direct Ca2+-sensitive and
Ca2+-insensitive PKC isoforms to membrane targets, and mediate
feedback modulation of Ca2+ signaling [102]. Furthermore, EGFR
signaling is transduced by two interconnected pathways, the
PLC-PKC and MAPK pathways, which interact at two points. PKC
activates MAPK, while MAPK can phosphorylate and activate
cPLA2. The AA produced by cPLA2 can act synergistically with
DAG to activate PKC [103], and AA can be further metabolized to
eicosanoids that in turn mediate signaling via G protein-coupled
receptors, and that may also induce HS response [104].
Moreover, AA can act within the cell, or it can cross cell mem-
branes and act on neighboring cells [99]. PIP2 is a substrate of
PI3K in the production of PIP3, another lipid with key signaling
functions and that plays a major role in the control of cell survival
(e.g., stress response), growth and proliferation. The components of
the PI3K pathway include upstream regulators of PI3K enzymes
(such as EGFR and Ras), PTEN, various Ser/Thr kinases and tran-
scription factors [105]. Several proteins propagate different cellular
signals after binding to PIP3, including Akt and Rac1, both of which
are important components of membrane-derived stress signal
pathways. In addition, membrane depolarization increases Hsp70
expression in cultured skeletal muscle cells, and this effect is crit-
ically dependent on Ca2+ released from IP3-sensitive intracellular
stores. Furthermore, depolarization-evoked slow Ca2+ signals
induce PKC-a activation and its translocation to the nucleus, favor-
ing HSF1 phosphorylation leading to increased Hsp70 expression
[106].
Gangliosides, sialic acid-containing glycosphingolipids (GSLs),
are expressed in a cell-type speciﬁc manner and they interact with
a variety of molecules on plasma membranes through different
non-covalent bonds, such as electrostatic and hydrophobic interac-
tions. Through these interactions, ganglioside family members par-
ticipate in diverse cell activities by forming dynamic functional
complexes in living cell membranes (membrane microdomains or
lipid raft) [107]. The expression of cellular gangliosides is inﬂu-
enced by various extracellular stimuli, including inﬂammatoryodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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domains may reﬂect the characteristics of individual cells in a
pathophysiological environment [108].
Insulin is critically dependent on caveolae/microdomains in adi-
pocytes [109,110]. Due to their lower density, these microdomains
can be isolated from cell membranes using sucrose gradient cen-
trifugation (after cell disruption with non-ionic detergents at cold
temperatures), and they are designated as ‘‘detergent-resistant
membrane microdomains’’ (DRMs: [111,112]). Though DRMs are
considered as experimental evidence of the existence of lipid rafts
and related domains, including caveolae and glycolipid-enriched
membrane microdomains (GEM: [111]), detergent-resistant mem-
branes should not be assumed to resemble biological rafts in size,
structure, or composition. Functional rafts may not be steady phe-
nomena; they might form, grow, cluster or break up, shrink, and
vanish according to functional requirements, regulated by rather
subtle changes in the activity of membrane disordering or ordering
compounds. However, these and other membrane domains have
important functions in cells, such as attracting proteins with which
they physically interact to propagate signals. Regulating these
domains through interventions acting on GSLs may be of interest
for the treatment of certain conditions, such as diabetes (see
below).
G protein coupled receptors (GPCRs) constitute the largest fam-
ily of receptors in humans, and they mediate a large number of cell
functions and currently constitute about 40% of all drug targets.
Pepducins are lipidated peptides that target the GPCR-G protein
interaction aided by a lipid tether, such as palmitic acid in speciﬁc
membrane microdomains [113]. For example, ATI-2341 targets the
ﬁrst intracellular loop of the chemokine receptor CXCR4 and
pepducin-induced activation of this receptor results in blood cell
mobilization, which is required prior to autologous bone marrow
transplantation [114].
Finally, raft microdomain remodeling by monounsaturated
(MUFA) MLT drugs regulates interactions with the Fas death ligand
receptor, which clusters in deﬁned membrane regions and
oligomerizes in a ligand-free manner to activate the extrinsic cas-
pase cascade, in this way selectively inducing leukemia cell death
[115].707
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7273.5. Type 5: direct MLT-drug binding to a protein that alters its
membrane binding afﬁnity or that of other signaling proteins
This mechanism of action (Fig. 2 panel 5) could be considered
within the scope of conventional chemotherapy, as the drug binds
to a protein rather than a lipid. However, the effect can be classed
as MLT when the drug’s molecular mechanism of action is depen-
dent on protein–lipid interactions (Fig. 2 panel 5). For example, far-
nesyl transferase and geranylgeranyl transferase inhibitors (e.g.,
Tipifarnib, which prevents Ras farnesylation) impair the binding
of Ras and related proteins to membranes. This compound is cur-
rently used in various anti-cancer combination therapy protocols,
and it prevents Ras from interacting with upstream (e.g., EGFR)
and downstream (e.g., Raf) signaling proteins [116]. Thus, this type
of drug indirectly inhibits the activity of the Ras-MAPK pathway by
impairing Ras binding to the membrane and its subsequent inter-
actions with other signaling partners [116]. Impairment of Ras
binding to the plasma membrane has been associated with inhibi-
tion of cancer cell proliferation and subsequent induction of differ-
entiation and death [41].728
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In the following sections, therapies that modulate the lipid
membrane that are currently under investigation are discussed.Please cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), htt4.1. Oncology
In the early 1980s, the anticancer drugs anthracyclines were
shown to kill cancer cells by a direct interaction with the plasma
membrane [117]. Agarose–doxorubicin complexes that cannot
enter the cancer cells kill them [117] by modulating the membrane
lipid structure, and subsequently altering the localization and
activity of important signaling proteins [29]. Based on this pioneer-
ing study [29], several drugs were designed to regulate the mem-
brane lipid structure with the aim of abolishing the off-target
interactions of anthracyclines and improving their efﬁcacy and
toxicity proﬁles [8,52,101,115].
This research led to the rational design of 2-hydroxyoleic acid
(Minerval) [101], which currently is in phase I/II clinical trials for
glioma. Its presence in membranes causes order reduction in
lamellar disordered regions (Ld, non-raft domains) [14,40,41]. In
addition, it speciﬁcally activates SGMS, inducing a marked increase
in SM levels in human cancer cells that enhances the order of the
ordered lamellar domains [40] (Lo, lipid rafts). Minerval activates
SGMS and induces dramatic increases in its product, SM, accompa-
nied by massive reductions in the levels of its substrate PE.
Treatment with Minerval causes normalization of membrane levels
of PE and SM, and increases ca. 10-fold the SM:PE ratio [40]. By
contrast, Minerval does not signiﬁcantly alter membrane lipid
composition in non-tumor cells, because the enzyme product
(SM) is found in high levels and its substrates (PC and PE) are lim-
iting. Thus, the changes induced in the lipid composition of cancer
cells appear to act as a functional switch that changes the cell sta-
tus from proliferating to quiescent. This compound selectively
induces the translocation of Ras from the membrane to the cyto-
plasm thus giving rise to MAP kinase pathway inactivation that
causes cell cycle arrest in cancer cells followed by cell death
[41,101,115].
Propofol-docosahexanoic acid (P-DHA) is another interesting
molecule with an MLT-related mechanism of action. This molecule
is a hybrid compound comprised of the anesthetic propofol cova-
lently bound to DHA [118]. The therapeutic activity of this com-
pound in vitro is unsurprising as both propofol and DHA alone
exert anticancer effects. Potent anti-cancer effects have also been
described recently for analogues of P-DHA, particularly for the
treatment of breast cancer [119]. Another MLT-based anticancer
drug is the alkyl lysophospholipid analogue edelfosine. This com-
pound and its analogues alter the membrane lipid raft microdo-
main structure, initiating a series of molecular events that result
in the induction of apoptosis in cancer cells [120]. However, due
to its toxicity and modest efﬁcacy, edelfosine could not complete
all clinical phases and be authorized for marketing for the treat-
ment of cancer.
Interestingly, the oncogenic antigen-519, a molecular marker
found in breast cancer patients with poor prognosis, has been iden-
tiﬁed as FA Synthase (FAS) [121]. The potential use of FAS inhibi-
tors is currently under investigation, and siRNA and chemical
inhibitors of this target (e.g., C75, ()-epigallocatechin-3-gallate)
selectively induce cell growth inhibition and apoptosis of cancer
but not normal cells in vitro [121,122]. Another chemical FAS inhi-
bitor, orlistat (marketed under the trade name Xenical by Roche in
most countries, and over-the-counter as Alli by GlaxoSmithKline in
the UK and US), blocks growth and induces cell death in breast can-
cer cells when administered concurrently with the monoclonal
antibody trastuzumab [123].
The alterations in lipid composition and lipid metabolism are
beginning to be associated with tumorigenesis and cancer patient
survival. For example, some lipid metabolism genes, such as,
OLR1 and GLRX are upregulated in breast and prostate cancer tis-
sues [124]. In this context, proteins related to fatty acid biosynthe-
sis and lipid metabolism regulation, such as, ACC, FASN, INSIG1,odulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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Table 1
Number of glioma (brain cancer) patients and expression of selected lipid genes.
Gene Down (n, %) Intermediate (n, %) Up (n, %)
ASAH2 115 (33.5%) 224 (65.3%) 4 (1.2%)
FASN 101 (29.4%) 234 (68.2%) 8 (2.3%)
SMPD2 0 (0%) 288 (84.0%) 55 (16.0%)
SMPD3 74 (21.6%) 269 (78.4%) 0 (0%)
PHYH 30 (8.7%) 311 (90.7%) 2 (0.6%)
SPTLC3 15 (4.4%) 197 (57.4%) 131 (38.2%)
SGMS1 84 (24.5%) 258 (75.2%) 1 (0.3%)
SGMS2 16 (4.7%) 254 (74.1%) 73 (21.3%)
SPHK1 6 (1.7%) 283 (82.5%) 54 (15.7%)
SPHK2 20 (5.8%) 292 (85.1%) 31 (9.0%)
UGCG 21 (6.1%) 283 (82.5%) 39 (11.4%)
Analysis of the expression of 11 representative genes related to lipid metabolism
and from the data of gene expression arrays from 343 patients with glioma taken
from the REMBRANDT database (Glioma Molecular Diagnostic Initiative) [128].
Genes are listed with standard abbreviations. Down: Gene (mRNA) expression
twofold below average. Intermediate: average expression. Up: twofold expression
above average. The altered expression of these genes was found to be highly
associated with changes in the median survival of the patent population and in ca.
90% of these glioma patients it was observed at least one alteration of the above
genes. Adapted from [47].
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12 May 2015and SREBP1 are highly expressed in breast cancer tumors and asso-
ciated with low patient survival [125] while colorectal carcinoma
risk has been associated with hepatic lipase polymorphisms
[126]. Analysis of the Cancer Genome Atlas (TCGA) database for
38 ovarian cancer samples demonstrated 39 differentially
expressed lipid genes in ovarian cancer tissue compared to normal
ovarian tissues [127].
Very recently the REMBRANDT database was analyzed to
explore the potential role of lipid metabolism in the prognosis of
individuals with brain cancer [128,129]. It was found that at least
twofold down-regulation of SMGS1 lowered very signiﬁcantly the
median of survival of patients with glioblastoma multiforme (a
type of brain cancer): from approx 18 months in patients with
intermediate expression to approx 10 months in patients with
SGMS1 downregulation [128]. Similar data were found in patients
with glioma [47]. Moreover, the 10-year survival of glioblastoma
multiforme patients with low SGMS1 expression was approx
10-fold lower than that of patients with normal SGMS1 expression.
These data indicate the possible relevance of SM and other lipid
metabolism genes in the malignant transformation in the various
types of cancer studied so far [40,41]. Moreover, the highly fre-
quent alterations in genes related to lipid metabolism induce a reg-
ulation in the median glioma patient survival from 22.6 months to
14.6 months ([47] and Table 1), further supporting the relevance of
membrane lipids in cell physiology and glioma etiopathology.
Similarly, tumors overexpressing fatty acid synthase (FAS), the
enzyme responsible for de novo synthesis of fatty acids, display
aggressive behavior compared to those tumors with normal FAS
levels, suggesting that FAS overexpression confers a selective
growth advantage. Glioblastoma multiforme patients overexpress-
ing FASN have a reduced median survival (approx 12 months) with
respect to patients with intermediate FASN expression (approx
28 months) [47,128].829
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8394.2. Metabolic diseases
4.2.1. Obesity
Administration or consumption of fats rich in the cis-MUFA,
oleic acid (x-9), is associated with lower body mass index (BMI)
values [130]. Moreover, in rats with ad libitum access to food, a
daily supplement of olive oil (in which oleic acid constitutes about
70–80% of all FAs) induces body weight reductions [131]. By con-
trast, the trans isomer of oleic acid, elaidic acid does not producePlease cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httbody weight decrease. Oleic and elaidic acid have the same chem-
ical composition, but their different molecular structure causes
divergent effects in the lipid bilayer structure [13], which has been
shown to be associated with their opposite impact on protein–lipid
interactions and human health [132]. In this context, the consump-
tion of saturated (or trans-MUFA) fats has been linked with obesity
and related health problems. Moreover, the saturated FA palmitic
acid is a known inducer of endoplasmic reticulum (ER) stress and
cell death [133]. Indeed, lipstatin, a potent natural inhibitor of pan-
creatic lipases and its derivative orlistat, a FAS (enzyme that
mainly produces palmitate) inhibitor and lipid absorption blocker,
are effective in the treatment of obesity [134].
4.2.2. Diabetes
Numerous studies demonstrate the association between the
type of dietary fats consumed and the development of diabetes,
which is placing a growing burden onmedical care services for per-
sons over 65 [135]. The ratio of saturated-to-unsaturated FAs in
erythrocyte membranes of diabetic patients is greater than that
observed in healthy controls (0.78 and 0.72, respectively) [136],
which indicates the close relationship between lipids and diabetes.
High oleic acid intake improves the glycemic status of these
patients and it also reduces the levels of saturated FAs, while
increasing those of unsaturated FAs, resulting in a reduction in
the saturated-to-unsaturated FA ratio from 0.78 to 0.66.
Moreover, it has been seen that concomitant with this effect, the
levels of various G proteins in these elderly diabetics are signiﬁ-
cantly regulated in blood cells [136]. In this scenario, treatments
with unsaturated FA derivatives have been shown to reduce glyce-
mia in rats [137], while other molecules that regulate lipid turn-
over and metabolism (e.g., orlistat, see above) prevent type 2
diabetes. This control of the membrane lipid composition in ani-
mals and humans after treatment with natural oleic acid or syn-
thetic analogues of this FA has been seen to be associated with
changes in the membrane lipid surface packing (nonlamellar HII
phase propensity), which regulates the interaction of some G pro-
teins (relevant in metabolic signaling) with the membrane
[8,13,136,137].
Membrane alterations affect signaling pathways from mem-
brane lipids to hsp genes and Hsps themselves play fundamental
roles in the etiology of several diseases, including type 2 diabetes
[2]. Typically, the decreased expression of stress proteins in
patients with type 2 diabetes correlates with reduced insulin sen-
sitivity, while activation of Hsp70 by heat therapy improves clini-
cal parameters [138,139]. The non-proteotoxic lipid-interacting
hydroxamic acid (HA) and its derivatives physiologically restore
the HS protein response, representing a new class of MLT pharma-
ceuticals [140]. At the molecular level HA derivatives are
broad-spectrum, multi-target compounds that stabilize mem-
branes and remodel their lipid rafts [79,81]. The HA derivative
BGP-15, currently being tested in clinical trials for the treatment
of diabetes (Table 1), remodels Chol-enriched lipid platforms in a
similar manner to that observed following non-lethal heat priming
or membrane stress [61,79]. BGP-15 also induces Hsp chaperone
expression through the Rac1 signaling cascade, in accordance with
the effects of Chol on the membrane-targeting of Rac1 (Fig. 3) [91].
Gangliosides (composed of a glycosphingolipid with one or
more sialic acids linked on the sugar chain) modulate a variety of
cellular processes (Fig. 4). TNFa produces a striking increase in cel-
lular ganglioside GM3 levels in mouse 3T3-L1 adipocytes in a state
of insulin resistance, and in the adipose tissues of obese/diabetic
rodents, including Zucker fa/fa rats and ob/ob mice [141].
Treatment of adipocytes with TNFa revealed that the increased
GM3 levels result in the elimination of insulin receptors (IRs) from
DRMs (while caveolin and ﬂotillin are retained), effectively dis-
rupting insulin metabolic signaling [142]. In agreement with theseodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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Table 2
Physiological features of the metabolic syndrome.
Organ/tissue Cellular characteristics
Pancreas b-cell growth and survival R
Glucose sensing R
Brain Appetite reduction R
Increased sympathetic tone S
Liver High free FAs and triacylglycerol secretion S
Reduced glucose production R
High lipoprotein uptake R
Fat High triacylglycerol synthesis S
Reduced lipolysis R
Macrophages Increased fat inﬁltration S
Increased survival R
Myocardium High glucose oxidation R
Decreased free fatty acid oxidation R
Arteries Low plaque formation R
R, insulin resistant; S, insulin sensitive.
Adapted from [208].
Fig. 4. Functional repertoire through ganglioside selection. (A) The core ganglioside
biosynthetic pathway. (B) Distinct differences between lipid rafts in individual T
cell subsets. Repertoire selection from immature thymocytes (CD4+ and CD8+
double positive) to mature single positive T cell subpopulations is accompanied by
selective ganglioside expression. Gene expression patterns and ganglioside analysis
conﬁrm that CD4+ T cells dominantly express a-series gangliosides due to GM3S
upregulation while CD8+ T cells carry o-series gangliosides due to the downreg-
ulation of GM3S and the upregulation of GM2/GD2S expression. These observations
suggest that each T cell subset contains unique rafts composed of different
ganglioside species, and that these rafts serve distinct functions during different
intracellular events following receptor-mediated stimulation. This ganglioside
selection process may be crucial for the formation of distinct and functional lipid
rafts in mature T cells.
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12 May 2015ﬁndings, insulin signaling is enhanced in mice lacking GM3 syn-
thase [143]. IRs form complexes with Cav1 and GM3 indepen-
dently, and in GM3-enriched membranes IR mobility is increased
by its dissociation from Cav1. As insulin metabolic signal transduc-
tion in adipocytes is critically dependent on caveolae [109,110], a
new pathological feature of insulin resistance in adipocytes has
been proposed, whereby the dissociation of the IR-Cav1 complex
occurs due to IR-GM3 interactions in DRM microdomains [144]
(Fig. 4). Thus, novel therapeutic interventions aimed at inhibiting
GM3 biosynthesis may prove beneﬁcial for the treatment of meta-
bolic diseases, including type 2 diabetes [108] (See Table 2).
Many receptor tyrosine kinases are localized in lipid rafts,
including growth factors EGFRs, PDGFRs, and insulin receptor
(IR), and all three of these receptor types carry a caveolin binding
motif in the cytoplasmic region [145]. Although the localization
of these receptors in caveolae is reportedly interrupted by elevated
levels of endogenous gangliosides, the precise mechanism underly-
ing this phenomenon has not been determined yet [146].
Interestingly, like IRs, some of these growth factor receptors con-
tain basic amino acids just above their transmembrane domains,
driving spatial proximity to GEM [144].897
898
899
9004.2.3. Hypercholesterolemia
Hyperlipidemia is a major risk factor for atherosclerosis and
cardiovascular disease, including coronary heart disease. Thus,Please cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), htthypercholesterolemia is a risk factor for atherosclerosis, stroke,
infarction, etc. [147]. The impact of high Chol on health is under-
scored by widespread use of Lipitor (atorvastatin), which is the
best-selling drug of all time [148]. In addition, high Chol levels
and alterations in Chol metabolism have been consistently associ-
ated with the development of Alzheimer’s disease (see
Section 4.4.1).
Chol is one of the main constituents of cell membranes, where it
plays structural and functional roles, contributing to the formation
of membrane microdomains (e.g., lipid rafts), which act as signal-
ing platforms [4,149]. Nevertheless, high LDL/VLDL-associated
Chol constitutes a major risk factor for the development of ather-
oma plaques that decrease the size of the lumen of blood vessels
thus increasing the likelihood of ischemic thrombi that cause
atherosclerosis, stroke and myocardial infarction [147,150]. In
addition, high plasma Chol levels are associated with increased
levels of Chol in the plasma membranes of cardiovascular and
other cells, resulting in altered membrane structure and cell signal-
ing [151].
4.2.4. Metabolic syndrome
Metabolic syndrome is deﬁned by the simultaneous occurrence
of various risk factors that collectively increase the probability of
developing type 2 diabetes mellitus and cardiovascular disease
[151,152]. High intake of saturated and x-6 FAs together with
low intake of oleic acid and x-3 FAs promotes the development
of metabolic syndrome, while the inverse combination prevents
its occurrence [153]. These data indicate that lipid derivatives, par-
ticularly FA-derived drugs, may play an important role in the treat-
ment of metabolic syndrome. Because 2-hydroxyoleic acid
efﬁcaciously controls most symptoms associated with this condi-
tion, it represents a serious candidate for monotherapy of meta-
bolic syndrome [131,132,154,155].
4.3. Cardiovascular diseases: hypertension
Human erythrocyte cell membranes of hypertensive individuals
contain more Chol, Chol esters and TAGs, and less phospholipids
than normotensive subjects, in association with alterations in G
protein activity [156]. In contrast, high oleic acid (MUFA) intakeodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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12 May 2015is associated with reduced blood pressure [157]. Moreover, the
synthetic hydroxy fatty acid, 2-hydroxyoleic acid (MUFA), induces
greater reductions in systolic blood pressure in hypertensive rats
than oleic acid [132,154]. This dramatic reduction in blood pres-
sure is mediated by the regulatory effects of membrane lipids,
which increase adenylyl cyclase activity, activate PKA and reduce
of Rho kinase expression [154].
Long chain x-3 FA intake also provoke a reduction in blood
pressure [158], while diets deﬁcient in these FAs are associated
with hypertension. Thus, dietary supplementation with
a-linolenic acid (18:3 x-3) reduces high blood pressure [159]. In
this context, the x-3 FAs, EPA and DHA, also induce blood pressure
reductions and protection against myocardial infarction and
ischemic stroke [160]. As described for MUFAs, polyunsaturated
FA (PUFA) intake inﬂuences the composition of the cell membrane,
which in turn regulates its structural properties and controls the
activity of membrane signaling proteins [161–163]. Finally, unsat-
urated FAs have been shown to have cardioprotective effects ([164]
and references therein). Thus, 2-hydroxyoleic acid controls the
transient outward K+ current (Ito) and the cytosolic Ca2+ transient
levels in isolated cardiomyocytes, which has been associated with
its normotensive effect [164]. By contrast, saturated FA and/or Chol
intake have negative effects on blood pressure [153].
Inﬂammatory responses are inhibited by
2-hydroxyarachidonate [165], which may prevent neuronal death
of brain penumbra area neurons after stroke, indicating its poten-
tial therapeutic use after post-ischemic events [137]. Various
unsaturated FA analogues have also been shown to prevent
atherosclerosis and improve cardiovascular health in general
[137]. Similarly, HA derivatives may be useful for the treatment
of atrial ﬁbrillation [166] due to their heat-stress-like effect, which
inﬂuences the abundance of Chol-microdomains.
4.4. Neurodegenerative disorders
After adipose tissue, the central nervous system (CNS) repre-
sents the largest location of lipids in the body. The myelin sheath
of neuronal axons is formed by glial cells and consists of a succes-
sion of lipid bilayers. Certain neurodegenerative disorders are asso-
ciated with demyelinization or signiﬁcant alterations in membrane
lipids. These facts and the capacity of lipid drugs to interact with
myelin and to cross the blood–brain-barrier (BBB) suggest that
MLT may play a major role in the treatment of CNS disorders.
4.4.1. Alzheimer’s disease
Alzheimer’s disease is the most common neurodegenerative
disease resulting in progressive dementia in the elderly (about
60–70% of all cases) [167]. The pathophysiology of Alzheimer’s dis-
ease is characterized by the loss of neurons and synapses, together
with the accumulation of extracellular deposits of ﬁbrillar
b-amyloid (Ab), known as senile plaques, and intraneuronal neu-
roﬁbrillary tangles that are generated by the abnormal hyperphos-
phorylation of tau protein [168]. However, Bapineuzumab (Pﬁzer,
ClinicalTrials.gov identiﬁer NCT00663026), an antibody directed
against Ab plaques, failed to induce improvements in a phase III
trial, which along with other ﬁndings suggests that these
alterations may be downstream of more fundamental molecular/-
cellular events that perhaps involve membrane lipid alterations.
In agreement with this suggestion, the efﬁcacy of acetyl-
cholinesterase inhibitors and NMDA blockers appears to be limited.
DHA is the most abundant FA in neuronal membranes in the
cerebral cortex gray matter (30–40% of all FAs esteriﬁed to mem-
brane phospholipids) and its decline is associated with age, and
with the loss of memory and learning that accompanies
Alzheimer’s disease [169,170]. Numerous epidemiological studies
have demonstrated an inverse association between Alzheimer’sPlease cite this article in press as: Escribá PV et al. Membrane lipid therapy: M
base for drug discovery and new disease treatment. Prog Lipid Res (2015), httdisease risk and x-3 PUFA dietary intake [171]. The biophysical
properties of DHA indicate that changes in its abundance may
cause alterations in amyloid precursor protein (APP) proteolysis,
receptor mediated signaling and Tau protein phosphorylation.
With the aim of reversing the structural and functional alterations
induced by DHA loss, 2-hydroxy-DHA (LP226A1, Lipopharma) was
designed, and tested in an animal model of severe Alzheimer’s dis-
ease (5XFAD mice). A 4-months treatment with this synthetic FA
increased neurogenesis and restored cognitive scores in the radial
maze test to control values [48,172]. In this context, c-secretase
cleavage occurs in an APP site located in the middle of the mem-
brane, suggesting that the lipid environment may inﬂuence the
production of amyloidogenic or non-amyloidogenic peptides, and
that it may therefore be involved in Alzheimer’s disease pathogen-
esis [173]. In addition, there is mounting evidence implicating Chol
in the pathogenesis of Alzheimer’s disease [174]. In fact, the
regulation of Chol turnover by means of statins has been shown
to reduce amyloid load [175,176]. Accordingly, biotech/pharma
companies are currently developing statin derivatives to
control Chol with a view to preventing or treating mild to
moderate Alzheimer’s disease (e.g., ClinicalTrials.gov Identiﬁer
NCT00024531).
4.4.2. Spinal cord injury and other neurological conditions
A neurotrophic lipid factor formed by binding oleic acid to albu-
min in vitro induces signiﬁcant motor recovery (40%) in rats with
spinal cord injury (SCI) [177] ameliorating both spasticity and pain.
By contrast, elaidic acid, which is the trans isomer of oleic acid,
causes no signiﬁcant improvements in paralysis, spasticity or pain.
Interestingly, oleic acid induces signiﬁcant changes in the mem-
brane structure, whereas elaidic acid has no such effect [13], indi-
cating that the action of the former is mediated by structural
effects. Similarly, LPA181, formed by the oleic acid analog, hydrox-
yoleic acid, and albumin, is more efﬁcacious than the latter induc-
ing motor recovery of 80%, and ameliorating spasticity and pain
[178].
HA and its derivatives may be useful for the treatment of broad
range of neurological and neuromuscular diseases, including amy-
otrophic lateral sclerosis [179], Huntington’s disease [180] and
muscular dystrophy [181].
Finally, x-3 and x-6 FA abnormalities have been implicated in
the development of psychiatric diseases, such as schizophrenia and
bipolar disorders [182,183], so that lipids may also be directly rel-
evant to certain psychiatric disorders.
4.5. Other pathologies
HA derivatives have been shown to have the potential to ame-
liorate diverse acute and chronic conditions such as retinopathy
[184], nephropathy [185], wound healing [186], acetaminophen
liver toxicity [187], chemotherapeutic neuropathy [188], intracra-
nial hemorrhage [189], atrial ﬁbrillation [190], sunburn [191],
ischemia reperfusion [192], vascular hypertension damage [193],
myocardial infarction [194], mercuric nephropathy [195], brain
hypoxia [196], pancreatitis [197], and ethanol intoxication [198].
Furthermore, MLT principles are being used to develop new
therapeutic drugs to treat infectious diseases. As the lipid compo-
sition of bacterial lipid bilayers greatly differs from that of eukary-
otic cells, it is possible to rationally design antimicrobial peptides
that speciﬁcally form pores in the prokaryotic envelope without
affecting the host, therefore overcoming resistance against other
conventional antibiotics [199,200]. In addition to the treatment
of bacterial infections, MLT approaches (i.e., edelfosine) have been
designed to treat eukaryotic parasite infections, such as leishmani-
asis [201]. Alkyl lysophospholipid derivatives (e.g., miltefosine) are
also currently under development (phase II) for the treatment ofodulation of the cell membrane composition and structure as a molecular
p://dx.doi.org/10.1016/j.plipres.2015.04.003
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12 May 2015antihistamine-resistant urticaria (ClinicalTrials.gov identiﬁer
NCT01170949). Moreover, these molecules have proven efﬁcacy
for the treatment of rheumatoid arthritis, atopic dermatitis,
cutaneous leishmaniasis, psoriasis and allergy [23,202].
AA is a relatively abundant FA in cells and it is a molecule
that can act as a precursor of inﬂammatory mediators (e.g., prosta-
glandins, leukotrienes, thromboxanes). The COX/LOX inhibitor
LP204A1 (AA analogue) readily crosses the BBB and prevents
neuronal death in the penumbra area, in which inﬂammatory
processes provoke the death of many neurons hours or days after
a stroke [137,165,203].1103
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11395. Future directions and conclusions
In summary, MLT has emerged as a novel and innovative
therapeutic concept that facilitates the design/discovery of new
molecules. Molecules developed using this strategy target the
membrane lipid boundary of cells and/or internal organelles,
where many cellular functions occur. The development of such
new drugs is aided by the identiﬁcation of the factors regulating
membrane lipid structures, and their roles in cell signaling and
pathophysiological processes, and such information has allowed
and will facilitate the design and discovery of novel molecules
for the treatment of important diseases. This new knowledge
may result in molecular modiﬁcations to improve the already
demonstrated efﬁcacy of MLT compounds or overcome certain lim-
itations associated with their use.
The great potential of therapies that modulate the plasma
membrane requires further contributions, such as new animal
model of disease based on known lipid alterations, and the study
of lipid alterations in existing animal models with the aim of eval-
uating MLT candidates. In addition, a deeper knowledge of mem-
brane lipid structure and its effects on protein localization,
protein–protein and –lipid interactions, cell signaling and patho-
physiology, would be necessary to discover or design new
membrane-interacting drugs. Given the current state of the art of
this ﬁeld, oncology, neurodegenerative disorders and cardiovascu-
lar diseases appear to be areas where treatments with drugs tar-
geted at the membrane could be highly efﬁcacious.1140
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